Vivesto Receives US Orphan Drug Status for Cantrixil
Vivesto received US orphan drug status for Cantrixil, a treatment for acute myeloid leukemia.
Related stories
LVMH Shares Hit 5-week High
LVMH shares increased to 399.55 EUR, the highest since September 2026. Over the past 4 weeks, LVMH gained 4.7%, and in the last 12 months, it decreased 34.75%.
L impact | EQUITY | Nov 03, 2026, 09:47 AM UTC
Tesla China-made EV sales rise 10.3% year over year in October
M impact | EQUITY | Nov 03, 2026, 09:46 AM UTC
Generic Engineering Q2 Consolidated Revenue From Operations INR 520.9 Million
M impact | EQUITY | Nov 03, 2026, 09:46 AM UTC
Generic Engineering Construction Q2 Net Profit INR 20.2 Million
M impact | EQUITY | Nov 03, 2026, 09:46 AM UTC
Zalando Q3 Revenue Rises 5.1% as B2B Revenue Jumps
Group revenue increased 5.1% to €3.17 billion and GMV rose 7.5% to €4.54 billion in the three months to September. B2B revenue jumped 27.9%. Zalando shares were up 1.9% at €27.51 i
M impact | EQUITY | Nov 03, 2026, 09:45 AM UTC
Zhongke Feice Chairman Proposes Share Buyback
Zhongke Feice said its controlling shareholder, chairman and general manager proposed repurchasing company shares for 1–1.5亿元.
L impact | EQUITY | Nov 03, 2026, 09:44 AM UTC